B Cell Therapy for Rheumatoid Arthritis: The Rituximab (Anti-Cd20) Experience

Annals of the Rheumatic Diseases - United Kingdom
doi 10.1136/ard.62.suppl_2.ii55
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Rituximab Therapy in Greek Patients With Rheumatoid Arthritis

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2008English

Non-Response to Rituximab Therapy in Rheumatoid Arthritis Is Associated With Incomplete Disruption of the B Cell Receptor Repertoire

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2019English

Regulation of CD20 in Rituximab-Resistant Cell Lines and B-Cell Non-Hodgkin Lymphoma

Clinical Cancer Research
Cancer ResearchOncology
2012English

Safety of Rituximab in Rheumatoid Arthritis

Reumatismo
Rheumatology
2011English

Clinical Impact of B-Cell Depletion With the Anti-Cd20 Antibody Rituximab in Chronic Fatigue Syndrome: A Preliminary Case Series

BMC Neurology
MedicineNeurology
2009English

Occupational Therapy for Rheumatoid Arthritis

2000English

Immunostimulant Therapy for Rheumatoid Arthritis

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
1976English

Obinutuzumab, a Potent Anti–B-Cell Agent, for Rituximab-Unresponsive IgM Anti-Mag Neuropathy

Neurology: Neuroimmunology and NeuroInflammation
Neurology
2018English

Anti-Inflammatory Drugs for Rheumatoid Arthritis

BMJ
1976English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy